[Form 4] Akebia Therapeutics, Inc. Insider Trading Activity
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Akebia Therapeutics director Ron Frieson received equity awards as part of his director compensation. He was granted 35,700 restricted stock units under the 2023 Stock Incentive Plan, increasing his direct common stock holdings to 165,200 shares. He was also granted stock options for 53,600 shares at an exercise price of $1.02 per share.
Both the RSUs and the stock options vest 100% on the first anniversary of the June 17, 2026 grant date, or earlier immediately before the first annual stockholders’ meeting after that date, if he continues serving the company through vesting.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
FRIESON RON
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to buy) | 53,600 | $0.00 | -- |
| Grant/Award | Common Stock | 35,700 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to buy) — 53,600 shares (Direct, null);
Common Stock — 165,200 shares (Direct, null)
Footnotes (1)
- The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date. The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
Key Figures
RSU grant size: 35,700 shares
Options granted: 53,600 options
Option exercise price: $1.02 per share
+4 more
7 metrics
RSU grant size
35,700 shares
Restricted stock units granted on June 17, 2026
Options granted
53,600 options
Stock options linked to common stock granted on June 17, 2026
Option exercise price
$1.02 per share
Strike price for 53,600 stock options
Post-grant common shares
165,200 shares
Total common stock directly held after RSU grant
Option expiration date
June 17, 2036
Expiration for the 53,600 stock options
Vesting schedule RSUs
100% after 1 year
RSUs vest on first anniversary or earlier before first annual meeting
Vesting schedule options
100% after 1 year
Options vest on first anniversary or earlier before first annual meeting
Key Terms
restricted stock units, 2023 Stock Incentive Plan, Non-Employee Director Compensation Program, Stock Option, +1 more
5 terms
restricted stock units financial
"The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
2023 Stock Incentive Plan financial
"were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan")"
Non-Employee Director Compensation Program financial
"as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program")"
Stock Option financial
"The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"The option to purchase shares ... with a $1.02 exercise price implied by the conversion_or_exercise_price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
What did Akebia Therapeutics (AKBA) director Ron Frieson report on this Form 4?
Ron Frieson reported equity awards from Akebia Therapeutics. He received 35,700 restricted stock units and 53,600 stock options as compensation, with no open-market purchases or sales, reflecting standard non-employee director compensation under the company’s 2023 Stock Incentive Plan and director compensation program.
What are the key terms of Ron Frieson’s Akebia (AKBA) stock option grant?
Frieson received options for 53,600 Akebia shares at a $1.02 exercise price. The options vest and become fully exercisable on the first anniversary of the June 17, 2026 grant date, or earlier immediately prior to the first annual stockholder meeting after that date, contingent on continued service.
When do Ron Frieson’s Akebia (AKBA) restricted stock units vest?
The 35,700 restricted stock units vest 100% on the first anniversary of the June 17, 2026 grant date. Alternatively, they can vest earlier immediately before the first annual meeting of Akebia’s stockholders after the grant date, provided Frieson continues serving the company until that vesting point.
Are Ron Frieson’s Akebia (AKBA) equity awards tied to a specific plan?
Yes, both the restricted stock units and stock options were granted under Akebia’s 2023 Stock Incentive Plan. They were issued pursuant to the company’s Fifth Amended and Restated Non-Employee Director Compensation Program, which governs how non-employee directors are compensated in equity.